Chronic Myeloid Leukemia (CML) Treatment Global Market Analysis, Trends, Growth, Research And Forecast 2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Chronic Myeloid Leukemia (CML) Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $10.4 billion In 2028 At A CAGR Of 6.2%.

The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $7.73 billion in 2023 to $8.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased awareness and early detection, clinical trial outcomes, targeted therapies development, patient advocacy and support groups, healthcare infrastructure development.

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, combination therapies, increasing patient access to novel therapies, government policies supporting orphan drugs, rising healthcare expenditure. Major trends in the forecast period include global collaboration in research, telemedicine and remote monitoring, development of next-generation tkis, treatment optimization strategies..

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12084&type=smp

Chronic Myeloid Leukemia (CML) Treatment Market Major Segments
The chronic myeloid leukemia (cml) treatment market covered in this report is segmented -

1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types
3) By Application: Hospitals, Clinic, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key Driver - Rising Incidence Of Chronic Myeloid Leukemia (CML)

The rising incidence and prevalence of chronic myeloid leukemia (CML) population is expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Chronic myeloid leukemia also known as chronic myelogenous leukemia, is a type of cancer that affects the bone marrow and blood. It is characterized by the overproduction of immature white blood cells called myeloid cells. Chronic myeloid leukemia (CML) treatment helps to slow the progression of cancer and stop it from reaching an advanced phase. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the rising incidence and prevalence of chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment market going forward.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12084&type=smp

Prominent Trend - Innovation In Drug Development For Better Treatment

Product Innovation is a key trend gaining popularity in the chronic myeloid leukemia (CML) treatment market. Companies operating in the chronic myeloid leukemia (CML) treatment market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Novartis, a Switzerland-based multinational pharmaceutical corporation, announced FDA (Foods and Drugs Association) approval of Scemblix (asciminib) for the treatment of chronic myeloid leukemia. Scemblix is the first FDA-approved CML treatment. Scemblix works by binding to the ABL myristoyl pocket and is used to treat patients who experience resistance and, or intolerance to currently available TKI therapies1-3. At 24 weeks, Scemblix outperformed Bosulif (bosutinib) in terms of major molecular response (MMR) rate (25% vs. 13%) and more than three times lower discontinuation rates due to adverse effects (7% vs. 25%).

Chronic Myeloid Leukemia (CML) Treatment Market Players
Major companies operating in the chronic myeloid leukemia (cml) treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, Bio-Path Holdings Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2023. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chronic Myeloid Leukemia (CML) Treatment Market Report Structure
3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies
4. Chronic Myeloid Leukemia (CML) Treatment Market - Macro Economic Scenario
5. Chronic Myeloid Leukemia (CML) Treatment Market Size And Growth
…..
27. Chronic Myeloid Leukemia (CML) Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.